Korea's Boryung Pharma Seeking MNCs To Sell Hypertension Product Abroad
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Boryung Pharma is seeking multinational partners to out-license its angiotensin receptor blocker Kanarb (fimasartan) in the U.S. and Europe